Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1)

This study has been completed.
Sponsor:
Collaborators:
Muscular Dystrophy Association
ALS Association
Information provided by (Responsible Party):
Isis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01041222
First received: December 30, 2009
Last updated: April 12, 2012
Last verified: April 2012

December 30, 2009
April 12, 2012
January 2010
December 2011   (final data collection date for primary outcome measure)
To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611 [ Time Frame: Safety analysis for dose escalation after Study Day 8 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01041222 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations

This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.

This study will test the safety, tolerability, and pharmacokinetics of single doses of ISIS 333611 administered as 12-hour intrathecal infusions. Four dose levels (0.15, 0.5, 1.5 and 3 mg) will be evaluated sequentially. The volume of the infusion is 0.25 mL/12 hours. Each dose level will be studied in a cohort of 8 patients where 6 are randomized to active treatment with ISIS 333611 and 2 are randomized to placebo.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Familial Amyotrophic Lateral Sclerosis
Drug: ISIS 333611
5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
  • Experimental: Arm 1
    0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
    Intervention: Drug: ISIS 333611
  • Experimental: Arm 2
    0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
    Intervention: Drug: ISIS 333611
  • Experimental: Arm 3
    1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
    Intervention: Drug: ISIS 333611
  • Experimental: Arm 4
    3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
    Intervention: Drug: ISIS 333611
  • Placebo Comparator: Placebo (phosphate buffered saline)
    Intervention: Drug: ISIS 333611
Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May;12(5):435-42. doi: 10.1016/S1474-4422(13)70061-9. Epub 2013 Mar 29.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
January 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical signs of weakness attributed to ALS.
  • Familial ALS with a documented SOD1 gene mutation.
  • Age 18 years or older.
  • Capable of providing informed consent and willing to comply with trial procedures and time commitments.
  • Vital capacity (VC) at least 50% predicted value for gender, height and age at screening and not using invasive respiratory support.
  • If taking riluzole, patients must be on stable dosage for at least 30 days prior to starting the study and expect to remain at that dosage until the end of the study.
  • Medically able to undergo temporary insertion of intrathecal catheter.
  • Normal test results for coagulation parameters.

Exclusion Criteria:

  • Treatment with another investigational drug for ALS (e.g. pyrimethamine, ceftriaxone, lithium, tamoxifen, arimoclomol, high dose creatine, biological agent, or device within 1-month of Screening or 5 half-lives of study agent, whichever is longer. No prior treatment with siRNA, cell transplant, or gene therapy is allowed.
  • Dosing in ISIS 333611-CS1 in a previous dose cohort within 60 days of screening.
  • Presence of any of the following clinical conditions:

    1. Drug abuse or alcoholism within one year of the Screening visit.
    2. Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic function, or active infectious disease.
    3. Documented history of HIV infection.
    4. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the Screening Visit.
  • Any condition that may impact intrathecal infusion including:

    1. History of structural spinal disease including tumors and hyperplasia.
    2. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter.
    3. Clinically significant abnormalities in hematology or clinical chemistry parameters as assessed by the Site Investigator during the Screening visit.
    4. Ongoing medical condition that according to the Site Investigator would interfere with the conduct and assessments of the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of study material or device performance, or would compromise the ability of the patient to undergo study procedures.
    5. ALT or AST >/= 3 x ULN, unless discussed with and approved by the Medical Monitor.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01041222
ISIS 333611- CS1
Yes
Isis Pharmaceuticals
Isis Pharmaceuticals
  • Muscular Dystrophy Association
  • ALS Association
Study Chair: Merit Cudkowicz, MD, MSc Massachusetts General Hospital
Study Chair: Timothy Miller, MD, PhD Washington University School of Medicine
Isis Pharmaceuticals
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP